Priority Briefs
Randy F. Sweis, Stefani Spranger, Riyue Bao, Gladell P. Paner, Walter M. Stadler, Gary Steinberg and Thomas F. Gajewski
Cancer Immunol Res July 1 2016 4 (7) 563-568; DOI:10.1158/2326-6066.CIR-15-0274
Immunotherapy resistance is a reality for many cancer patients. Three tumor-intrinsic molecular pathways, β-catenin, PPARγ, and FGFR3, were identified and linked to the exclusion of T cells from urothelial tumors. Targeting these pathways may enhance immune checkpoint efficacy.